Provention Bio Inc. (PRVB) Misses Q3 EPS by 13c

Provention Bio Inc. (NASDAQ: PRVB) reported Q3 EPS of ($0.56), $0.13 worse than the analyst estimate of ($0.43).

"We are excited about the progress the Provention Bio team has made in recent months as we work to redefine the treatment landscape for T1D and other autoimmune diseases," stated Ashleigh Palmer, CEO, Provention Bio. "Earlier this week, we announced our achievement of a major milestone with the completion of the rolling BLA submission for teplizumab for the delay or prevention of clinical T1D in at-risk individuals. In parallel with our regulatory efforts, we are focused on preparing for a potential product approval and launch in mid-2021. We recently introduced two national campaigns to educate key stakeholders about early-stage T1D and the potential advantages of screening populations at risk of developing clinical-stage disease. In parallel with teplizumab, we are advancing our portfolio of additional therapeutic candidates targeting the interception or prevention of autoimmune disease. We recently initiated a Phase 2 trial for PRV-015, an anti-IL-15 human monoclonal antibody which, if approved, has the potential to be the first therapeutic for the treatment of non-responsive celiac disease."

For earnings history and earnings-related data on Provention Bio Inc. (PRVB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c